{ "docId": "019de515-e815-738a-9db4-c54117f0c213", "docSlug": "5b4399e5f29e85eea5be20288be8cb74", "documentTitle": "Bluejay | Investor Presentation Deck | 18 slides", "authorId": "bluejay", "authorName": "Bluejay Diagnostics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-06-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 5, "pageCount": 18, "prevPage": 4, "nextPage": 6, "slideType": "market_sizing", "function": "size_opportunity", "density": "overcrowded", "nDataPoints": 24, "notes": null, "elementsJson": null, "metadataConfidence": 1, "imagePath": null, "slideHref": "/slides/019de515-e815-738a-9db4-c54117f0c213/5", "deckHref": "/decks/019de515-e815-738a-9db4-c54117f0c213", "deckJsonHref": "/decks/019de515-e815-738a-9db4-c54117f0c213.json", "deckAnchorHref": "/decks/019de515-e815-738a-9db4-c54117f0c213#slide-5", "components": [ { "bbox": { "h": 0.04, "w": 0.343, "x": 0.503, "y": 0.803 }, "kind": "callout", "text": "raise TAM to $1.8 B", "attrs": {}, "subkind": "primary", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "0ad0e285-0bf4-4895-b7f5-9c54f3499edd", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.04, "w": 0.343, "x": 0.147, "y": 0.803 }, "kind": "callout", "text": "increase testing volumes by 54.6%", "attrs": {}, "subkind": "primary", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "0b3d2c18-de08-43d9-addb-0cf69ca3e3a0", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.04, "w": 0.08, "x": 0.035, "y": 0.92 }, "kind": "image", "text": "bluejay\nDIAGNOSTICS", "attrs": {}, "subkind": "logo", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "28ae369e-3190-41d4-be17-cc052c08723b", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.07, "w": 0.449, "x": 0.138, "y": 0.889 }, "kind": "list", "text": "1Harmony Healthcare: https://harmony.solutions/understanding-care-long-term-acute-care-hospitals-101/\n2National Center for Health Statistics, National Hospital Ambulatory Medical Care Survey, 2020\n3Frost & Sullivan primary research\n4Bluejay pricing expectations per IL-6 test under DRG coding\nThe Symphony™™ System and Symphony™ Cartridge have not been cleared or approved by the U.S. FDA", "attrs": {}, "subkind": "bullet", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "b8a8bcb1-f6f1-414b-8486-32fe56777ca7", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.018, "w": 0.621, "x": 0.179, "y": 0.754 }, "kind": "paragraph", "text": "Bluejay's Symphony has potential to expand use of IL-6 testing in acute care settings:", "attrs": {}, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "f854b32c-4885-4b54-9dd2-7ac49a188b23", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.04, "w": 0.919, "x": 0.039, "y": 0.154 }, "kind": "paragraph", "text": "Potential testing revenue from IL-6 testing in long-term acute care facilities (LTACs), emergency departments (EDs), and intensive care units (ICUs)", "attrs": {}, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "ff94ed31-6cc1-4fa7-b868-6d04b3a92931", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.015, "w": 0.349, "x": 0.615, "y": 0.948 }, "kind": "source-note", "text": "Copyright ©2023 Bluejay Diagnostics, Inc. All rights reserved in all slides | June 2023 5", "attrs": {}, "subkind": null, "toolName": null, "toolSlug": null, "confidence": null, "componentId": "64bfe8cf-7adf-4c0c-90ff-c7e2e3224ffd", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.46, "w": 0.929, "x": 0.035, "y": 0.256 }, "kind": "table", "text": "DESCRIPTION\nNumber of patients\nPercentage of patients with clinician ordered IL-6 tests³\nAverage number of IL-6 tests ordered for each patient³\nEstimated number of IL-6 tests performed\nCost per test to the lab4\nTotal Addressable Market for IL-6 testing\nTesting increase expected with Bluejay's Symphony IL-6 test³\nTotal Addressable Market with Bluejay's Symphony IL-6 test\nLTACs\n400,0001\n27.5%\n3.4\n0.37 M\n$150\n$56.1 M\n26.4%\n$70.9 M\nICUs\n3,100,0002\n26.5%\n3.7\n3.0 M\n$150\n$453.5 M\n57.7%\n$714.9 M\nEDs\n5,345,0002\n23.5%\n3.5\n4.4 M\n$150\n$663.2 M\n54.9%\n$1,027.3 M", "attrs": {}, "subkind": "data", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "a0fe3f1f-dc89-4447-9aa7-5e6f42e6db30", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.03, "w": 0.92, "x": 0.039, "y": 0.09 }, "kind": "title", "text": "$1.2 Billion Total Addressable IL-6 Testing Market in Acute Care Settings (US Annual)", "attrs": {}, "subkind": "headline", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "918c5b30-0e30-4235-b86a-b640bd4a2816", "frameworkName": null, "frameworkSlug": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 5, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "155a99ef-cd6f-469b-92cd-328ac487de6a", "evidence": "The deck presents the Symphony IL-6 Test as a solution, highlighting its potential clinical advantages and market opportunity", "position": 1, "objective": "Why is Bluejay Diagnostics' Symphony IL-6 Test important for improving patient outcomes?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.6, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }